Cartalax

Cartalax is a synthetic tripeptide composed of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp, single-letter code AED). Molecular weight is 333.29 g/mol. The sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein important for cartilage extracellular matrix organization. Cartalax was originally identified from kidney peptide extract analysis at the St. Petersburg Institute of Bioregulation and Gerontology and subsequently characterized for cartilage-related effects.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. Cartalax is positioned as the cartilage Cytogen.

The AED tripeptide is the shortest of the Khavinson Cytogens at three residues. It shares the AED core with Cardiogen (AEDR tetrapeptide for cardiac tissue), Epitalon (AEDG tetrapeptide for pineal), and Cortagen (AEDP tetrapeptide for cortex). The shared AED core suggests common upstream chromatin-binding chemistry, with the C-terminal extensions claimed to direct tissue specificity. The plausibility of strict tissue-selective targeting from such minimal sequence differences remains debatable in independent reviews.

The Evidence

The compound-specific evidence base consists of:

Chondrocyte and fibroblast proliferation work. Cell culture studies have reported that Cartalax stimulates proliferation of chondrocytes and fibroblasts in both young and aged rat tissue cultures. The effect is observed at picomolar to nanomolar concentrations consistent with the broader Khavinson framework.

Aging marker modulation. Cartalax exposure in cell culture has been associated with:

• Reduction in pro-apoptotic p53 expression
• Reduction in senescence-associated p16 and p21 expression
• Increase in SIRT6 expression (associated with longevity in animal models)
• Reduction in MMP-9 activity (matrix-degrading enzyme)
• Modulation of Ki-67 proliferation marker

Skin fibroblast studies (Linkova et al., 2016). Cartalax effects on skin fibroblasts during in vitro aging documented restoration of proliferation rates and matrix protein synthesis patterns characteristic of younger cells.

Kidney cell renewal (Khavinson 2014). Studies in organotypic kidney tissue cultures from young and aged rats reported that Cartalax promotes cellular proliferation, extending the proposed mechanism beyond cartilage tissue.

Independent Western confirmation is sparse. PubMed indexing returns predominantly Khavinson-affiliated publications. No registered ClinicalTrials.gov trial exists for Cartalax as of May 2026.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Sold as a biologically active dietary supplement.

WADA. Not on 2026 Prohibited List.

The proposed mechanism is consistent with the broader Khavinson short-peptide bioregulation framework, with claimed cartilage-tissue specificity through structural similarity to type XI collagen.

Type XI collagen connection. The AED sequence corresponds to a motif in the alpha-1 chain of type XI collagen, providing the structural rationale for cartilage-targeting. Type XI collagen plays a key role in regulating type II collagen fibril diameter and overall cartilage extracellular matrix organization. The proposed model is that the AED tripeptide acts as a signaling mimetic of this collagen motif, providing feedback signaling to chondrocytes about extracellular matrix status.

Cellular entry and nuclear localization. AED is hypothesized to enter chondrocytes and other cells through peptide transporters, reach the nucleus, and modulate gene expression. The two acidic residues (Glu, Asp) and one neutral residue (Ala) provide a net negative charge under physiological conditions, supporting hypothesized interactions with histone proteins and nucleic acids.

Senescence pathway modulation. Cartalax exposure has been associated with reduction in pro-apoptotic p53 expression and senescence markers p16 and p21, alongside increase in SIRT6 expression. The combined effect pattern is positioned as "anti-senescence" cellular reprogramming, though independent confirmation in transcriptomic studies is limited.

Cartilage-specific effects. In chondrocyte cultures, Cartalax has been reported to:

• Stimulate proliferation in both young and aged cells
• Reduce apoptosis under stress
• Modulate extracellular matrix gene expression
• Affect inflammatory cytokine production
• Inhibit matrix metalloproteinase activity (MMP-9 specifically)

Pharmacokinetics. Tripeptides face significant gut hydrolysis after oral administration. The Khavinson framework proposes signaling at the gut-mucosa interface propagated systemically. Direct measurement of intact Cartalax in plasma after administration has not been published.

Human pharmacokinetic data is not published.

Cell culture and animal model data report:

• Stimulation of chondrocyte proliferation in young and aged rat models
• Stimulation of skin and other fibroblast proliferation
• Reduction in senescence-associated markers (p16, p21)
• Reduction in pro-apoptotic p53 expression
• Increase in SIRT6 expression
• Inhibition of cartilage-degrading MMP-9
• Effects on kidney epithelial cell renewal
• Possible chondroprotective effects in animal osteoarthritis models

Research-chemical user reports describe subjective improvements in joint comfort and recovery from athletic training. Reports are uncontrolled, unverified for vial identity, and confounded by simultaneous lifestyle modifications. The osteoarthritis-treatment positioning that some vendors emphasize is not supported by any controlled human trial.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Cartalax.

Russian retail Cartalax is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 20 mg of active peptide.

Research-chemical Cartalax is sold as lyophilized powder in 20 mg vials. Subcutaneous protocols in user communities typically use 200 to 500 mcg per day over 10 to 20 day cycles. Some user protocols use higher doses of 1 to 5 mg per day. These doses are extrapolated from generic Khavinson recommendations and lack Cartalax-specific human pharmacokinetic support.

The course-and-cycle pattern is standard Khavinson protocol. Optimal cycle spacing for Cartalax has not been independently validated.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation for Cartalax lists individual intolerance, pregnancy, and lactation as contraindications. No serious adverse events have been reported in Russian-language publications.

The constituent amino acids (alanine, glutamic acid, aspartic acid) are common dietary amino acids. Tripeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure. Acute toxicity is mechanistically unlikely.

Long-term human safety data with controlled endpoints does not exist. Theoretical concerns specific to chronic use:

• Effects on chondrocyte proliferation with chronic high-dose exposure are uncharacterized
• The reported effects on senescence pathways (p16, p21, p53 reduction; SIRT6 elevation) could in principle affect tumor surveillance; this concern has not been formally evaluated
• Drug-drug interactions with NSAIDs, intra-articular corticosteroids, hyaluronic acid injections, and disease-modifying osteoarthritis drugs have not been studied
• Effects in patients with rheumatoid arthritis, gout, or other inflammatory arthropathies have not been evaluated

The compound's claimed effects on cellular senescence markers, if accurate, would warrant more careful long-term safety evaluation than has been performed.

Within the Khavinson system, Cartalax is the synthetic cartilage Cytogen. The standard Cytogen-then-Cytomax sequence does not have a widely marketed cartilage-specific Cytomax counterpart, so Cartalax is typically used as a standalone Cytogen or paired with other tissue-specific compounds.

For musculoskeletal-focused stacks, Cartalax combines with research-chemical peptides like BPC-157 and TB-500 (broader tissue-healing claims), though the combination has not been studied in any controlled setting. For broader Khavinson geroprotective protocols, Cartalax joins Epitalon, Cardiogen, and other organ-specific bioregulators.

External pharmaceutical comparators for osteoarthritis and cartilage health have varied evidence bases:

• NSAIDs (oral and topical) for symptomatic relief, substantial Phase 3 evidence
• Intra-articular corticosteroid injections for acute flares, established short-term efficacy
• Intra-articular hyaluronic acid for knee osteoarthritis, mixed evidence base
• Glucosamine and chondroitin sulfate as widely used supplements with mixed evidence
• Surgical interventions (arthroscopy, osteotomy, joint replacement) for advanced disease
• Weight management and exercise therapy as first-line evidence-based interventions

Cartalax has no comparable evidence base for any specific musculoskeletal indication and is not a substitute for evidence-based osteoarthritis care.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.